As experts warn of an impending third wave and forewarn of how the raging pandemic going forward could infect children more, news has come in that Hyderabad-based Bharat Biotech has received approval from India’s drugs regulator to conduct clinical trials of its COVID-19 vaccine Covaxin on children.
This indeed holds out a glimmer of hope as Covaxin is the first Covid-19 vaccine to be tested on on children between 2 and 18 years of age in India.
To evaluate its efficacy among children and ascertain its imunogenicity, the trial is expected to be conducted among 525 participants at multiple locations including All India Institute of Medical Sciences (AIIMS), Delhi, and AIIMS Patna.
Vaccine for children must be a pririty area now considering that vaccine jabs have begun in the US for those below 18 years of age as well already to protect them from the coronavirus. India must pave the way for global vaccines to the country to tide over this acute shortage of vaccines we are now faced with to ensure both young and old can get their jabs.